Tumor NLRP3 inflammasome activity mediates resistance to Anti-PD-1 immunotherapy in advanced gastroesophageal cancer

被引：0
|
作者：
Yarla, Nagendra
Howell, Kaylee
Y-Van Nguyen
Niedwiecki, Donna
Uronis, Hope
Strickler, John
DeVito, Nicholas C.
Theivanthiran, Bala
Hanks, Brent A.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-7521
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7521
引用
收藏
页数：2
相关论文
共 50 条
  • [21] NLRP3 Inflammasome Upregulates PD-L1 in Ovarian Cancer and Contributes to an Immunosuppressive Microenvironment
    Pan, Wenjing
    Jia, Zhaoyang
    Du, Jingtong
    Chang, Kexin
    Liu, Yiming
    Liu, Wei
    Zhao, Xibo
    Tan, Wenhua
    IMMUNOTARGETS AND THERAPY, 2024, 13 : 775 - 788
  • [22] Apatinib remodels the immunosuppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy
    Luo, Qicong
    Dong, Zinan
    Xie, Wen
    Fu, Xiaoteng
    Lin, Lingyun
    Zeng, Qiang
    Chen, Yinggang
    Ye, Guodong
    Chen, Maoli
    Hu, Huiyu
    Wang, Lin
    Xie, Yuanyuan
    Cai, Wangyu
    CELL REPORTS, 2023, 42 (05):
  • [23] How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC
    Chen, Li
    Jiang, Xiaoying
    Li, Yuanheng
    Zhang, Qiqi
    Li, Qing
    Zhang, Xiaoyan
    Zhang, Meng
    Yu, Qiongfang
    Gao, Dian
    CLINICAL IMMUNOLOGY, 2022, 237
  • [24] Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer
    Wang, Yue
    Pattarayan, Dhamotharan
    Huang, Haozhe
    Zhao, Yueshan
    Li, Sihan
    Wang, Yifei
    Zhang, Min
    Li, Song
    Yang, Da
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [25] Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation
    Yu, Man
    Peng, Zhengxin
    Qin, Min
    Liu, Yang
    Wang, Jingning
    Zhang, Cai
    Lin, Jiaming
    Dong, Tianqi
    Wang, Lulu
    Li, Shasha
    Yang, Yongqin
    Xu, Shan
    Guo, Wencong
    Zhang, Xiao
    Shi, Mingjun
    Peng, Huiming
    Luo, Xianwen
    Zhang, Huixia
    Zhang, Li
    Li, Yan
    Yang, Xiang-Ping
    Sun, Shuguo
    MOLECULAR CELL, 2021, 81 (06) : 1216 - +
  • [26] APPLICATION OF THE SITC IMMUNOTHERAPY RESISTANCE TASKFORCE DEFINITIONS OF ANTI-PD-1 RESISTANCE TO STUDIES EVALUATING PATIENTS WITH ADVANCED MELANOMA
    Shui, Irene
    Scherrer, Emilie
    Frederickson, Andrew
    Druyts, Eric
    Tawbi, Hussein
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A339 - A339
  • [27] Glyco-signatures in patients with advanced lung cancer during anti-PD-1/PD-L1 immunotherapy
    Cao, Xinyi
    Hu, Zhihuang
    Sheng, Xiangying
    Sun, Zhenyu
    Yang, Lijun
    Shu, Hong
    Liu, Xiaojing
    Yan, Guoquan
    Zhang, Lei
    Liu, Chao
    Zhang, Ying
    Wang, Huijie
    Lu, Haojie
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2024, 56 (08) : 1099 - 1107
  • [28] Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer
    Ju, Mingyi
    Bi, Jia
    Wei, Qian
    Jiang, Longyang
    Guan, Qiutong
    Zhang, Ming
    Song, Xinyue
    Chen, Ting
    Fan, Jingyi
    Li, Xiaojuan
    Wei, Minjie
    Zhao, Lin
    BRIEFINGS IN BIOINFORMATICS, 2021, 22 (04)
  • [29] Role of DAMPs for immunoresistance towards anti-PD-1 immunotherapy in advanced melanoma
    Geidel, G.
    Bauer, A. T.
    Wicklein, D.
    Schumacher, U.
    Schneider, S. W.
    Gebhardt, C.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 (03) : E110 - E110
  • [30] Anti-PD-1 agent: A promising immunotherapy drug for oral cancer?
    Balachander, Kannan
    Paramasivam, Arumugam
    ORAL ONCOLOGY, 2022, 132
12345